722 related articles for article (PubMed ID: 29116021)
1. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
2. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
4. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
[TBL] [Abstract][Full Text] [Related]
5. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.
Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689
[TBL] [Abstract][Full Text] [Related]
8. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.
Wang WY; Lin TY; Twu CW; Tsou HH; Lin PJ; Liu YC; Huang JW; Hsieh HY; Lin JC
Oncotarget; 2016 Jul; 7(27):42608-42616. PubMed ID: 27191654
[TBL] [Abstract][Full Text] [Related]
11. Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Lee VH; Kwong DL; Leung TW; Choi CW; Lam KO; Sze CK; Ho P; Chan WL; Wong LS; Leung D
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):42-9. PubMed ID: 26482452
[TBL] [Abstract][Full Text] [Related]
12. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
14. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
[TBL] [Abstract][Full Text] [Related]
15. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
16. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
17. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
[TBL] [Abstract][Full Text] [Related]
19. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma.
Le QT; Jones CD; Yau TK; Shirazi HA; Wong PH; Thomas EN; Patterson BK; Lee AW; Zehnder JL
Clin Cancer Res; 2005 Aug; 11(16):5700-7. PubMed ID: 16115906
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
